

## **QUADRON CAPITAL CORPORATION**

Suite 1620 - 609 Granville Street

Vancouver, BC V7Y 1C3

Phone: 1-866-824-8938

### **News Release**

## **QUADRON ANNOUNCES EXECUTION OF DEFINITIVE AGREEMENT WITH SOMA LABS SCIENTIFIC INC.**

**Vancouver, British Columbia, November 10, 2015:** Quadron Capital Corporation (the "Company" or "Quadron") is pleased to announce that it has entered into a definitive amalgamation agreement, dated November 6, 2015, pursuant to which a wholly-owned subsidiary of Quadron will amalgamate (the "Acquisition") with Soma Labs Scientific Inc. ("Soma Labs"). Soma Labs is an arms' length private company incorporated under the laws of British Columbia.

Soma Labs is a BC-based laboratory and research facility established to provide services to the biotech and bioceutical industries, including analytical and laboratory services, organic compound extractions, distillations, purification, formulation and process development.

Soma Labs has entered into a three year, \$1.5 million services contract with Odorchem Manufacturing Corp ("Odorchem"), pursuant to which Soma Labs is providing research for the scientific development of new odor control processes and formulations for Odorchem. Odorchem produces high quality non-toxic odor control solutions for industrial, commercial and residential applications and requires a laboratory with advanced research capabilities for the development of new and ongoing product formulations.

This continuous research and development will help generate new revenue opportunities and market growth for Soma Labs as it expands its products and services to a variety of markets and industries. Soma Labs' services and operations within the odor control business will seamlessly transfer to other sectors including the cannabis and algae space.

The acquisition of Soma Labs is part of Quadron's strategy to concentrate on revenue generation and capitalize on the burgeoning opportunity in the legal cannabis industry.

For more information, visit: [www.somalabs.ca](http://www.somalabs.ca)

On closing of the Acquisition, security holders of Soma Labs will receive 17,422,500 common shares and 2,000,000 preferred shares of Quadron in exchange for all of their common and preferred shares of Soma Labs. Subject to Soma Labs achieving \$1,000,000 in earnings before interest, taxes, depreciation and amortization for the 2016 fiscal year, each preferred share will automatically convert into one common share of Quadron. The holders of Soma Labs convertible securities will also receive convertible securities of Quadron on a one-for-one basis. The Acquisition is not expected to constitute a reverse-take-over under applicable securities laws.

Quadron further announces that it has closed on a non-brokered private placement of 6,640,000 units at \$0.10 per unit for gross proceeds of \$664,000. Each unit is comprised of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.20 per share for 24 months the date of issuance. If at any time during the 24 months, Quadron completes a going public transaction, the expiry date will be amended to 18 months following the closing of the going public transaction. All the securities issued in the financing will have a 4 month hold period expiring March 7, 2016.

Closing of the Acquisition remains subject to a number of conditions, including the receipt of all required shareholder approvals and third party consents, and satisfaction of other customary closing conditions. The Acquisition cannot close until the required approvals are obtained. There can be no assurance that the Acquisition will be completed as proposed or at all.

The Company also announces that effective November 5, 2015, Scott Ackerman has joined the board of directors.

For further information, contact Doug McFaul at (778) 331-8505.

On behalf of the Board of Directors of  
**QUADRON CAPITAL CORPORATION**

Doug McFaul  
Director

*Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.*